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Synopsis: Revisions are presented for the two FIGO systems describing structured 
normal uterine bleeding and abnormal uterine bleeding symptoms, and the PALM-
COEIN classification of potential causes.  
 
ABSTRACT 
Background: The International Federation of Gynecology and Obstetrics (FIGO) 
systems for nomenclature of symptoms of normal and abnormal uterine bleeding 
(AUB) in the reproductive years (FIGO AUB System 1) and for classification of 
causes of AUB (FIGO AUB System 2; PALM-COEIN) were first published together in 
2011. The purpose was to harmonize the definitions of normal and abnormal 
bleeding symptoms and to classify and subclassify underlying potential causes of 
AUB in the reproductive years to facilitate research, education, and clinical care. The 
systems were designed to be flexible and to be periodically reviewed and modified 
as appropriate. 
Objectives: To review, clarify, and, where appropriate, revise the previously 
published systems.  
Methodology and outcome: To a large extent, the process has been an iterative one 
involving the FIGO Menstrual Disorders Committee, as well as a number of invited 
contributions from epidemiologists, gynecologists, and other experts in the field from 
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around the world between 2015 and 2017. Face-to-face meetings have been held in 
Rome, Vancouver, and Singapore, and have been augmented by a number of 
teleconferences and other communications designed to evaluate various aspects of 
the systems. Where substantial change was considered, anonymous voting, in some 
instances using a modified RAND Delphi technique, was utilized.   
 
1. Introduction 
The worldwide impact of abnormal uterine bleeding (AUB) in the reproductive years 
is substantial, with a prevalence of approximately 3%–30% among reproductive 
aged women. The reasons for the wide spectrum of estimates are unclear but vary 
with age, being higher in adolescents and in the fifth decade of life, and varying 
somewhat with country of origin [1–9]. Approximately one third of women are 
affected at some time in their life [3, 6]. Many of the published studies are restricted 
to estimates of the prevalence of the symptoms of heavy menstrual bleeding (HMB); 
when other symptoms, particularly those of irregular and intermenstrual bleeding are 
included, the prevalence rises to 35% or higher [9]. 
 
Available evidence suggests that as many as half of affected women do not seek 
medical care, even if they have access to a healthcare provider [4, 5, 8], a 
circumstance that may explain the variation in reported prevalence. The 
manifestations vary from modest to severe disruption of work productivity and quality 
of life [10, 11], and increasing maternal morbidity and mortality for pregnant women 
with pre-existing AUB-related anemia [12, 13].  
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In 2011, recognizing the international need created by the impact of AUB, the 
International Federation of Gynecology and Obstetrics (FIGO), published a pair of 
systems and a set of clinical recommendations with the aim of informing and aiding 
clinicians and investigators in the design and interpretation of investigations into AUB 
in the reproductive years, as well as the provision of evidence-based clinical care 
[14].  
The present manuscript was designed to provide a detailed update on the FIGO 
recommendations concerning terminologies, definitions, and underlying causes of 
AUB in the reproductive years. Revised terminologies and definitions of normal 
menstrual parameters, and the symptoms of AUB were initially published in 2007 
[15, 16], while the seminal 2011 publication [14] presented both systems—
Terminology and Definitions (FIGO-AUB System 1) and Classification of Causes of 
AUB in the Reproductive Years, the PALM-COEIN system (FIGO-AUB System 2). 
From the beginning, it was determined that these recommendations should be 
flexible and subject to ongoing regular review to incorporate results of new research 
and analysis. These review periods were intended to broadly coincide with the 
triennial FIGO World Congresses. 
The first key recommendations, published simultaneously in 2007 in Fertility Sterility 
and Human Reproduction [15, 16], recommended a substantial revision of existing 
terminologies and definitions for the description of AUB features and, by doing so, 
redefined the normal parameters of menstrual bleeding. Recommended was the 
abolition of terms (largely of Latin and Greek origin) such as menorrhagia, 
metrorrhagia, and dysfunctional uterine bleeding, which were poorly defined, used 
internationally in a disparate manner, and had no consistent meaning for the general 
and academic communities [15–17]. 
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The second key publication [14] presented a novel and pragmatic approach to 
classification of the underlying causes of AUB in non-pregnant women. No such 
systematic classification of underlying causes existed at that time. This 2011 
manuscript introduced the PALM-COEIN classification based on clinical- and 
imaging-based stratification of causes into “structural” pathologies that can be 
“imaged” and/or defined histopathologically (Polyps, Adenomyosis, Leiomyomas and 
Malignancy or atypical endometrial hyperplasia; PALM). The remaining causes were 
categorized as “non-structural”, in that they cannot be imaged, but clinical 
assessment with detailed history and appropriate physical examination, sometimes 
supported by laboratory testing, can largely imply or make a diagnosis of cause 
(Coagulopathies, Ovulatory disorders, primary Endometrial disorders, Iatrogenic and 
Not otherwise classified; COEIN). 
 
It rapidly became clear that each of these individual causes could require division 
into subclassifications of cause and phenotype to optimize clinical management and 
support the broad spectrum of research needed. The subclassification of 
leiomyomas was an obvious starting point [14]. Three key publications [14–17] 
formed the foundation of a simple, flexible, and educationally sound pair of 
descriptive systems that were designed to provide a quick initial clinical direction of 
diagnosis and management, but also to be flexible enough to provide effective 
linkages with laboratory and research aspects. 
 
The present report updates the FIGO recommendations for both FIGO-AUB Systems 
1 and 2, including clarifications on terminologies and definitions, as well as 
modifications in the PALM-COEIN system that include reassignment of some 
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entities, and guidance for subclassification of leiomyomas, much of which has been 
preliminarily published [18–20]. These changes represent structured deliberative 
processes that include use of a modified RAND Delphi process applied to the 
attendees of a series of FIGO Menstrual Disorders Committee (MDC) sponsored 
expert meetings. To allow this report to function independently, and to provide 
context, there exists substantial but necessary overlap with the original publication 
[14], and with other subsequent and related publications produced by the MDC since 
2011 [21 ][18–20, 22–24] 
 
The FIGO MDC is currently working on subclassification systems for adenomyosis 
and endometrial polyps. The adenomyosis subclassification system is the most 
advanced and will be published soon in preliminary form with planned validation 
studies to follow. The polyp system is being developed but a release date has not yet 
been determined. There is consideration for subclassification systems for AUB-C, -
O, -E, and –I, but these initiatives are still in the very early stages of development.  
 
It is important that clinicians recognize that these FIGO systems relate solely to 
assessment and management of nongestational AUB. There are other causes of 
genital tract bleeding and urinary tract or gastrointestinal bleeding that do not come 
from the uterus. These can usually be identified by an appropriate case history and 
physical examination. 
2. Acute versus chronic nongestational AUB in the reproductive years 
In the original system [14], FIGO introduced the concept of nongestational acute 
AUB in the reproductive years, distinguishing it from chronic AUB—an approach 
endorsed by the American College of Obstetricians and Gynecologists [25]. These 
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definitions remain unchanged for 2018. Chronic nongestational AUB in the 
reproductive years is defined as bleeding from the uterine corpus that is abnormal in 
duration, volume, frequency, and/or regularity, and has been present for the majority 
of the preceding 6 months. Acute AUB, on the other hand, is defined as an episode 
of heavy bleeding that, in the opinion of the clinician, is of sufficient quantity to 
require immediate intervention to minimize or prevent further blood loss. Acute heavy 
menstrual bleeding may present in the context of existing chronic AUB or can occur 
absent such a background history.   
 
3. FIGO-AUB system 1 
Revision of terminologies and definitions of symptoms of abnormal uterine 
bleeding 
The revised FIGO-AUB System 1 is seen in Figure 1, with changes summarized in 
Table 1. As determined by the multinational process described in the original 
publications [14–16], terms such as menorrhagia, metrorrhagia, oligomenorrhea, and 
dysfunctional uterine bleeding have been abandoned. There is acknowledgement of 
the specific changes in menstrual bleeding patterns that may be encountered at 
each end of the reproductive spectrum (i.e. in adolescence or the peri-menopause) 
[26]. 
 
 
Preparation of the present 2018 recommendations is the result of sequential reviews 
of the FIGO-AUB System 1 initially proposed in 2007 and 2009, and underwent slight 
modification for 2011. The current revisions represent deliberations in meetings held 
in 2012, 2015, and 2017. These reviews have included comment, detailed 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
questioning, and recommendations from many clinicians from around the world but 
have only resulted in minor changes and refinement of definitions from the original 
system. 
 
In this revision of FIGO AUB System 1, the definition of irregularity has been 
changed from one where the shortest to longest variation is up to 20 days, to 
variation of 7–9 days, depending upon age (18–25 years ≤9 days; 26–41 years ≤7 
days; 42–45 years ≤9 days) [27]. For practical purposes, this normal variation in 
cycle length can be alternatively expressed as ±4 days. 
 
Formally included is the term HMB, a symptom (not a diagnosis), that has been 
defined (in clinical situations) by the National Institute for Health and Clinical 
Excellence as “excessive menstrual blood loss, which interferes with a woman's 
physical, social, emotional and/or material quality of life” [5, 28].  
 
4. FIGO AUB system 2 
Revision of classification of underlying causes of AUB (PALM-COEIN) 
Highlights of changes since the original publication in 2011 [14] are summarized in 
Table 2. The basic/core classification system is almost unchanged and is presented 
in Figure 2. There remain the nine main categories, arranged according to the 
acronym PALM-COEIN (pronounced “palm-koin”): Polyp; Adenomyosis; Leiomyoma; 
Malignancy and hyperplasia; Coagulopathy; Ovulatory dysfunction; Endometrial 
disorders; Iatrogenic; and Not otherwise classified. Category N has undergone a 
change from “not yet classified” to “not otherwise classified” as we cannot be certain 
which, if any, of these entities will ultimately be placed in a unique category. The 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
components of the PALM group are generally discrete (structural) entities that can 
be evaluated or measured visually using some combination of imaging techniques 
and histopathology; the COEI group comprises entities that are not defined by 
imaging or histopathology (non-structural). By its nature, the “Not otherwise 
classified” category includes a spectrum of potential entities that may or may not be 
measured or defined by histopathology or imaging techniques. 
 
The system has been constructed with the understanding that a given patient may 
have one or more entities that could cause or contribute to AUB symptoms and that 
structurally definable entities, such as adenomyosis, leiomyomas, and endocervical 
or endometrial polyps are often asymptomatic and, therefore, may not contribute to 
the presenting symptoms. 
 
Since the original publication of the FIGO AUB systems [14], there has been some 
progress in the diagnosis of adenomyosis, although its relationship to reproductive 
function and uterine bleeding is still under investigation. It has been demonstrated 
that two-dimensional transvaginal ultrasonography has similar sensitivity and 
specificity for the diagnosis of adenomyosis when compared to magnetic resonance 
imaging (MRI) [29, 30]. There is some progress regarding the spectrum of two-
dimensional ultrasonography findings associated with the diagnosis [31, 32], but no 
consensus regarding how many and which of these findings are necessary before 
there is reasonable certainty that a diagnosis of adenomyosis is present. The eight 
criteria suggested by the morphological uterus sonographic assessment (MUSA) 
group are shown in Figure 3 [31]. The FIGO MDC is currently working on an 
international consensus for an imaging-based adenomyosis classification system 
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designed to phenotype the disorder in a standardized fashion that should facilitate 
research, education, and clinical care. However, for diagnosis the use of the 
transvaginal ultrasonography-based MUSA criteria [31] for the diagnosis of 
adenomyosis for the purposes of FIGO AUB System 2 is suggested. 
 
The only subclassification system ratified so far is the leiomyoma subclassification 
system, essentially unchanged since the initial 2011 publication [14] (Figure 4). The 
only subtle difference is for Type 3 myomas, where contact with the endometrium is 
a feature shared by other submucous leiomyomas (Types 0, 1, and 2), whereas 
intramural location, without focal distortion of the endometrial cavity, is a 
characteristic of Types 4 and higher. The system now recognizes this area of 
overlap. It is also recognized that there are some difficulties in applying the 
leiomyoma subclassification system to the spectrum of leiomyomas that can be 
encountered, especially in large uteri with multiple leiomyomas [33]. There is now 
more detailed guidance for distinguishing amongst the leiomyoma subtypes.  
 
Distinguishing between Type 0 and 1, and between Type 6 and 7 leiomyomas is now 
accomplished by comparing the stalk diameter to the mean diameter of the 
leiomyoma. Types 0 and 7 now comprise leiomyomas that have a stalk diameter that 
is 10% or less than the mean diameter of the leiomyoma. Hysteroscopy has now 
been deemed the standard for distinguishing between a Type 2 and 3 leiomyoma, 
with the determination based upon the lowest filling pressure that allows visualization 
of the endometrial cavity. Distinguishing between Type 4 and Type 5 leiomyomas 
should be based upon observation of distortion of the serosa (Type 5) as determined 
by ultrasonography or MRI. 
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FIGO now provides additional guidance for investigators using the FIGO 
subclassification system for leiomyomas. A minimal data set for describing 
leiomyomas should include an estimate of total uterine volume based on imaging 
(transabdominal or transvaginal ultrasonography or MRI), as well as an estimate of 
the number of leiomyomas (1, 2, 3, 4, or greater than 4). If such imaging is not 
available, such as may be the case in low-resource countries, the minimum data set 
should include an estimate of uterine size on clinical examination as equivalent to a 
gravid uterus of “X” weeks. When transvaginal ultrasonography or MRI are available, 
the location (anterior, posterior, left, right, or center) and the estimated volume of up 
to four individual leiomyomas should be recorded. Additionally, the location in the 
vertical plane should be described; upper half, lower half, or both. When more than 
four are present, the volume of the largest leiomyoma should be recorded, as a 
minimum. If other leiomyomas are judged to be of equal or greater relevance for 
clinical decision making based on location, the volume of these lesions should be 
recorded as well. If the endometrium is visualized, then the relationship between the 
documented myomas and the endometrium should be described using the FIGO 
classification system. 
 
Women with AUB and associated malignant or premalignant lesions of the uterus 
(e.g. endometrial carcinoma, leiomyosarcoma, and atypical endometrial hyperplasia 
sometimes, referred to as endometrial intraepithelial neoplasia or EIN [34, 35]), are 
categorized as having AUB-M. Their categorization is further defined using existent 
WHO and FIGO classification and staging systems [36, 37]. 
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AUB associated with the use of selected categories of systemic pharmacotherapy or 
intrauterine systems or devices, is classified as “iatrogenic” [38]. In addition to 
gonadal steroids such as estrogens, progestins, and androgens, and agents that 
directly affect their production or local function, this category now includes 
nonsteroidal pharmaceuticals that contribute to ovulatory disorders, such as those 
that affect dopamine metabolism, including phenothiazines and tricyclic 
antidepressants. In the original categorization, women with AUB associated with the 
use of anticoagulants were categorized with coagulopathies (AUB-C); in this 
revision, they are considered iatrogenic and classified as AUB-I.  This includes the 
modern, non-vitamin-K antagonists such as rivaroxaban that appears to have a 
greater impact on the volume of menstrual bleeding than the traditional, vitamin K 
antagonists, typified by warfarin [39, 40]. 
 
Category “N”, “not otherwise classified” was created in the original system to 
accommodate entities that are rarely encountered or are ill defined. These include, 
but are not limited to, entities such as arteriovenous malformations (AVMs) [41] and 
the lower segment or upper cervical niche or “isthmocele” frequently found in 
association with previous cesarean delivery and sometimes attributed to as a cause 
of AUB [42, 43]. 
 
 
5. Notation 
After the patient has undergone appropriate investigation, discussed below, she 
could be found to have one or more potential causes of, or contributors to, the AUB 
symptoms. Consequently, the system has been designed to enable appropriate 
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multi-category notation. While it is recognized that this increased level of complexity 
will be of most value to specialists and researchers, it should have utility for any 
healthcare provider. 
 
This approach has been designed following the example of the WHO TNM staging of 
malignant tumors, with each component addressed for all women investigated for 
AUB symptoms using the two FIGO AUB Systems. For example, if an individual was 
suspected to have a disorder of ovulation, a type 2 leiomyoma, and no other 
anomalies, they would be categorized as follows in the context of a complete 
evaluation: AUB P0 A0 L1(SM) M0 - C0 O1 E0 I0 N0. It was recognized that in clinical 
practice the use of such full notation might be considered cumbersome, so an option 
for abbreviation has been developed. The abbreviated FIGO description of the 
patient previously described would be AUB-LSM; -O.  
 
FIGO now encourages clinicians and investigators to consider the use of a matrix for 
the evaluation of patients with AUB in the reproductive years (Figure 5). This allows 
for the identification and documentation of the status of the investigation. 
 
6. Recommendations for clinical investigation 
A woman presenting with AUB may have one or a number of factors that may 
contribute to the genesis of the symptoms. Using FIGO AUB System 1 to define the 
types of AUB symptoms present is a prerequisite to evaluation for the elements in 
FIGO AUB System 2. A number of pathological entities (e.g. subserous leiomyoma) 
may be present that are possibly or even unlikely to be a contributor to the 
symptoms. Consequently, the investigation of women with AUB during the 
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reproductive years must be undertaken in as comprehensive but practicable fashion 
given the clinical situation and the available resources, with the findings carefully 
interpreted for their role in the symptoms. For example, available evidence would 
suggest that a single 1-cm polyp would not be the cause of the symptom of HMB. A 
suggested approach is illustrated in Figure 6A and 6B, and described in brief below.  
 
General assessment 
When evaluating a woman of reproductive age with either acute or chronic genital 
tract bleeding thought to be AUB, the clinician should ensure that the bleeding is not 
related to pregnancy, and is emanating from the cervical canal, rather than another 
location such as the vagina, vulva, perineum, or perianal region. Pregnancy may be 
reliably confirmed with a urine or serum assay for the presence of the β-subunit of 
human chorionic gonadotropin (hCG). It is to be noted that determination of the 
location or viability of a pregnancy is not considered to be within the domain of the 
FIGO-AUB systems. Women with both acute and chronic AUB should be evaluated 
for iron deficiency, if possible, with serum ferritin, and for related anemia by 
measuring hemoglobin and/or hematocrit (preferably a full blood count, including 
platelets). Once the bleeding has been confirmed, or suspected, to originate in the 
cervical canal or endometrial cavity, the clinician should systematically evaluate the 
patient for each of the components of FIGO AUB System 2, the PALM-COEIN 
classification. 
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Determination of ovulatory status 
Predictable cyclic menses every 24–38 days are usually (but not always) associated 
with ovulation whereas bleeding associated with ovulatory disorders is typically 
irregular in timing and flow, and often interspersed with episodes of amenorrhea.  
 
If, largely based on FIGO AUB System 1, a woman is found to have AUB related to a 
ovulatory disorder, she is to be categorized as AUB-O. If there is uncertainty 
regarding ovulatory status, measurement of serum progesterone, timed to the best 
estimate of mid-luteal phase, may be useful for confirming ovulation in the current 
cycle. Whereas endometrial biopsy is not recommended as a method for 
determination of ovulatory status, when performed and appropriately indicated—to 
evaluate for the presence of premalignant or malignant endometrial change—
histopathological findings reflecting secretory change may confirm that ovulation has 
occurred. 
 
 
Screening for systemic disorders of hemostasis 
A structured history is a useful and effective screening tool. FIGO suggests a tool 
that has been demonstrated to have 90% sensitivity for the detection of these 
relatively common disorders (coagulopathies) [44] (Table 3). For those with a 
positive screening result, further testing is necessary, often following consultation 
with a physician with a special interest in disorders of coagulation, such as a 
hematologist. Such tests may include assays for von Willebrand factor, Ristocetin 
cofactor, partial thromboplastin time (PTT) and other measures [45]. If the results are 
positive, the woman with AUB would be being categorized as having AUB-C. 
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Previously, by convention, individuals with AUB associated with the use of 
anticoagulant therapy were categorized as AUB-C, but they now are included in the 
AUB-I category. 
 
 
 
Evaluation of the endometrium 
Endometrial sampling is not required for all patients with AUB, so it is necessary to 
identify the women for whom endometrial biopsy is appropriate. Selection for 
endometrial sampling is based on a combination of risk factors for the presence of 
premalignant or malignant changes, comprising some combination of age, personal, 
and genetic risk factors, and TVUS screening for endometrial echo-complex 
thickness [5, 46–49]. Although some studies have indicated that age is not important 
as an independent variable [47], most suggest that endometrial sampling be 
considered for all women over a certain age, usually 45 years [5]. It is also evident 
that obesity contributes significantly to the risk of premalignant and malignant 
change in the endometrium, a feature that increases the risk of endometrial 
neoplasia even in young women in the third and fourth decades of life [50]. Women 
with a family history of hereditary nonpolyposis colorectal cancer syndrome, now 
called Lynch Syndrome, have a lifetime risk of endometrial cancer of up to 60%, with 
the mean age at diagnosis of 48–50 years [51, 52]. Regardless of the clinical 
guideline, when AUB is persistent and either unexplained or inadequately treated, 
endometrial sampling is necessary—if possible—in association with hysteroscopic 
evaluation of the uterine cavity [28]. Sonohysterography is likely a reasonable 
substitute for hysterography to diagnose for polyps and submucous leiomyomas [53–
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55]. There exist a number of techniques for endometrial sampling, but it is important 
that an adequate sample be obtained before the patient can be considered at low 
risk for a malignant neoplasm [56].  
 
It is apparent that a relationship exists between chlamydial infection of the 
endometrium and AUB. Consequently, it may be prudent to consider evaluating for 
the presence of the organism in symptomatic patients [57]. Although cervical assays 
seem reasonable, the relationship between cervically obtained specimens and the 
presence of absence of endometrial infection is unclear [58].  If chronic endometritis 
is identified, patients should be categorized as having AUB-E. 
 
Evaluation of the structure of the endometrial cavity 
Evaluation for structural abnormalities affecting the endometrial cavity is performed 
to identify abnormalities—including endometrial or endocervical polyps and 
submucous leiomyomas—that could contribute to AUB. Transvaginal 
ultrasonography (TVUS) is an appropriate and important screening tool and, in most 
instances, should be performed early in the course of the investigation. Ideally, the 
ultrasonography system must be of adequate quality to clearly display both 
myometrial and endometrial features, and the examiner should have the ability to 
operate the scanning device and interpret the images displayed. Regardless, TVUS 
is not 100% sensitive even in ideal circumstanced because polyps and other small 
lesions may elude detection, even in the context of a normal study [59, 60]. 
If good ultrasonic images fail to show findings suggestive of endometrial polyps or 
submucous leiomyomas, the clinician may initially presume that the structure of the 
endometrial cavity is normal. However, if there are imaging features that indicate the 
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presence of endometrial polyp(s), if there are leiomyomas that may encroach on the 
endometrial cavity, or if the examination is suboptimal, imaging with more sensitive 
techniques is recommended. These generally include hysteroscopy and/or 
transvaginal ultrasonography with intrauterine contrast, either gel or saline, termed 
sonohysterography. Which of these techniques is used will depend on the resources 
available to the clinician [53–55]. In most instances, sonohysterography will be more 
readily available, particularly when the only available resources for hysteroscopy 
reside in an operating room. However, if office hysteroscopy is available, there may 
be additional value, particularly when polyps are suspected, as hysteroscopically 
directed polypectomy will be feasible in the same setting.  
 
In some parts of the world, notably in the UK (managed by the British National 
Health Service), there is an emphasis on conducting investigation and management 
of the symptom of HMB at the first consultation (“One stop management”, including 
key history, examination, transvaginal ultrasonography, and hysteroscopy, if 
indicated, at the same visit) [28]. This type of management has been assisted by the 
systematic application of the two FIGO AUB Systems – clearly defining the 
symptoms using FIGO AUB System 1, and then, following an appropriately 
structured evaluation, categorization of the findings or assessments using FIGO AUB 
System 2, the PALM-COEIN classification. 
 
When vaginal access is difficult or impossible, a circumstance often encountered 
with adolescents and virginal women, TVUS, contrast sonohysterography, and office 
hysteroscopy may not be feasible. In such instances, there is a role for MRI. 
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Alternatively, hysteroscopic examination with indicated biopsies, performed under 
appropriate anesthesia may be the best approach. 
 
With the PALM-COEIN classification, the presence of a polyp or polyps (AUB-P) is 
confirmed only with documentation of one or more clearly defined polyps, generally 
with either hysteroscopy or sonohysterography. Usually, a patient may be 
categorized with one or more submucous leiomyomas (AUB-LSM) with either 
sonohysterography or hysteroscopy. When using either, the clinician should take 
care to infuse the distending medium with low pressure so that the natural 
relationships of the leiomyoma with the endometrium and myometrium are distorted. 
As described above, FIGO now recommends that the distinction between Type 2 
and 3 leiomyomas be based upon hysteroscopy performed using the lowest 
pressure necessary to evaluate these relationships. The use of sonohysterography 
for this purpose is considered to be a suitable and more practical substitute in a 
variety of clinical situations.  
 
Myometrial assessment  
For the primary leiomyoma categorization, the myometrium is assessed primarily 
with a combination of TVUS and transabdominal ultrasonography to identify 
leiomyomas, with any such identified lesion leading to an “L” assignment. For the 
secondary subclassification, it is necessary to determine the relationship (contact or 
not) of the endometrium with the leiomyoma by performing some combination of 
TVUS, contrast sonohysterography, hysteroscopy, and MRI. Should one or more 
submucous leiomyomas be found (Types 0, 1, 2, or 3) then the woman is stated to 
have LSM, if only Type 4, 5, 6, 7, and/or 8 are identified, the categorization is Lo. 
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Tertiary subclassification of leiomyoma type requires that the clinician clarify the 
relationship of the leiomyomas with the endometrium, endometrial cavity, 
myometrium, and uterine serosa. At least for those leiomyomas that do not distort 
the endometrial cavity (Type 0, 1, & 2), this distinction requires the use of imaging, 
either ultrasonography, or, more accurately MRI as described previously. 
 
The myometrium should also be evaluated for the presence of adenomyosis or to 
distinguish between leiomyomas and localized collections of adenomyosis or 
adenomyomas [31, 61]. The sonographic and MRI criteria for the diagnosis of 
adenomyosis are described elsewhere in the present document. While the FIGO 
MDC is currently developing a system for the classification of adenomyosis, for the 
present, an assignment of AUB-A is best based on imaging findings consistent with 
TVUS as described above [31] (Figure 3) or, if available, using MRI [30]. Although 
promising for the diagnosis of adenomyosis, the role of both three-dimensional 
TVUS [62, 63] and sonographic elastography [64, 65] is still a subject of 
investigation. 
 
If available, MRI may be necessary for evaluation of the myometrium to distinguish 
between leiomyomas and adenomyosis. MRI imaging may also be superior to TVUS, 
sonohysterography, and hysteroscopy for measuring the myometrial extent of 
submucous leiomyomas [59]. However, reliance on MRI is currently impractical, 
especially for low-resource nations, because of the relative or absolute lack of 
access within many healthcare systems [66]. 
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7. Discussion 
AUB in women of reproductive age is a manifestation of any of a number of 
disorders or pathologic entities. The FIGO systems for nomenclature and symptoms 
(System 1), and for classification of potential causes of AUB in the reproductive 
years (System 2) are designed to facilitate both basic science and clinical 
investigation, as well as the practical, rational, and consistent application of medical 
and surgical therapy for affected women. The current revisions of the two FIGO-AUB 
systems are designed to clarify and modify, in a fashion that should improve the 
utility of these systems for research, education, and clinical care. Clinicians, 
educators, and investigators are encouraged to use the matrix concept to guide the 
evaluation of women afflicted with chronic AUB, as well as acute AUB once the 
patient is stabilized (Figure 7).  
 
These systems, and their continued and appropriate revision, represent a 
collaboration involving clinicians, investigators, and other informed participants from 
six continents. This participation was designed to develop an implementable System 
1 and to provide input into the practicality of performing the investigations described 
for categorizing according to System 2, the PALM-COEIN classification. Currently, 
the routine characterization of structural lesions of the uterus using MRI is not 
feasible and its use is not included as a mandatory tool for evaluating patients with 
chronic AUB. This does not mean that clinicians cannot or should not use MRI if it is 
deemed necessary and is available, with the results used to categorize leiomyoma 
type or determine the presence, absence, or location and extent of adenomyosis. 
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8. Conclusion 
The present paper reports the changes to both FIGO AUB systems based on 6 years 
of analysis, discussion, and debate since the original publication. The original 
seminal publications presented effective approaches to the terminologies and 
definitions around AUB (System 1), followed by development of a novel classification 
(PALM-COEIN) of underlying causes of abnormal uterine bleeding in the 
reproductive years (System 2) [14]. These developments and refinements are 
integrated into the whole FIGO-AUB model in this manuscript. 
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Figure 1 FIGO AUB System 1. Nomenclature and Definitions of AUB Symptoms 
For 2018, intermenstrual bleeding has been added, and there is now a practical 
definition for irregular menstrual bleeding created by using the 75th percentile, 
effectively excluding the occasional long or short cycles experienced by many 
women. The available evidence suggests that, using these criteria, the normal range 
(shortest to longest) varies with age: 18–25 years of age, ≤9 days; 26–41 years, ≤7 
days; and for 42–45 years, ≤9 days Harlow et al., 2000 [27].  For clinical purposes, 
the definition of HMB proposed by the UK National Institute for Health and Care 
Excellence has been adopted – “Excessive menstrual blood loss which interferes 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
with a woman’s physical, social, emotional, and/or material quality of life”. 
Abbreviations: AUB, abnormal uterine bleeding; FIGO, International Federation of 
Gynecology and Obstetrics; HMB, heavy menstrual bleeding. 
 
 
Figure 2 FIGO AUB System 2. PALM-COEIN System for Classification of Causes of 
AUB in the Reproductive Years. The basic system comprises four categories that are 
defined by visually objective structural criteria (PALM: Polyp; Adenomyosis; 
Leiomyoma; and Malignancy and hyperplasia), four that are unrelated to structural 
anomalies (COEI: coagulopathy; Ovulatory dysfunction; Endometrial disorders; 
Iatrogenic causes), and one reserved for entities categorized as “Not otherwise 
classified”. The leiomyoma category (L) is subdivided into patients with at least one 
submucous myoma (LSM) and those with myomas that do not impact the endometrial 
cavity (Lo). Modified with permission from [67]. Abbreviations: AUB, abnormal uterine 
bleeding; FIGO, International Federation of Gynecology and Obstetrics. 
 
 
Figure 3 Adenomyosis diagnostic criteria. Graphical depictions of the eight TVUS 
criteria proposed by the MUSA group are presented. These include asymmetrical 
myometrial thickening (A); myometrial cysts (B); hyperechoic islands (C); fan shaped 
shadowing (D); echogenic subendometrial lines and buds (E); translesional 
vascularity (F), where present; irregular junctional zone (G); and an interrupted 
junctional zone (H). Identification and evaluation of the junctional zone may best be 
accomplished with three-dimensional ultrasonography. For the present at least, the 
presence of two or more of these criteria are highly associated with a diagnosis of 
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adenomyosis. Reproduced with permission from [31]. Abbreviations: MUSA, 
Morphological Uterus Sonographic Assessment; TVUS, transvaginal 
ultrasonography. 
 
Figure 4 FIGO leiomyoma subclassification system. Classification system including 
the FIGO leiomyoma subclassification system. The system that includes the tertiary 
classification of leiomyomas categorizes the submucous group according to the 
original Wamsteker et al. system [68] and adds categorizations for intramural, 
subserosal, and transmural lesions. Intracavitary lesions are attached to the 
endometrium by a narrow stalk (≤10% or the mean of three diameters of the 
leiomyoma) and are classified as Type 0, whereas Types 1 and 2 require a portion of 
the lesion to be intramural—with Type 1 being less than 50% of the mean diameter 
and Type 2 at least 50%. Type 3 lesions are totally intramural but also abut the 
endometrium. Type 3 are formally distinguished from Type 2 with hysteroscopy using 
the lowest possible intrauterine pressure necessary to allow visualization. Type 4 
lesions are intramural leiomyomas that are entirely within the myometrium, with no 
extension to the endometrial surface or to the serosa. Subserous (Types 5, 6, and 7) 
leiomyomas represent the mirror image of the submucous leiomyomas—with Type 5 
being at least 50% intramural, Type 6 being less than 50% intramural, and Type 7 
being attached to the serosa by a stalk that is also ≤10% or the mean of three 
diameters of the leiomyoma. Classification of lesions that are transmural are 
categorized by their relationship to both the endometrial and the serosal surfaces. 
The endometrial relationship is noted first, with the serosal relationship second (e.g. 
Type 2–5). An additional category, Type 8, is reserved for leiomyomas that do not 
relate to the myometrium at all, and would include cervical lesions (demonstrated), 
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those that exist in the round or broad ligaments without direct attachment to the 
uterus, and other so-called “parasitic” lesions. Modified with permission from [67]. 
Abbreviation: FIGO, International Federation of Gynecology and Obstetrics. 
 
Figure 5 FIGO AUB System 2 diagnostic matrix. A simplified diagnostic matrix is 
illustrated in the left pane. Each of the primary classification system elements are 
listed. If a patient has not been completely evaluated for a potential cause it is listed 
in the “?” column, if evaluation has demonstrated no evidence of the abnormality the 
“N” column is checked, and if assessment is positive, an X is placed in the 
appropriate box. An example is shown in the panel on the right. The patient has the 
symptom of HMB, and interim assessment, including contrast hysterosonography 
documented in the left matrix has revealed a subserosal leiomyoma designated as 
Lo. However, the patient had a positive historical screening result for coagulopathy 
and hematological assessments for coagulation disorders are not yet available. 
Consequently, the “C” and “E” rows remain in the “?” category. The hematological 
assessment demonstrates that there is no evidence of coagulopathy, so the 
diagnosis of a primary disorder of endometrial hemostasis is made. The C row can 
now be assigned an “N” while the E category can be checked as “Y”. Abbreviations: 
AUB, abnormal uterine bleeding; FIGO, International Federation of Gynecology and 
Obstetrics; HMB, heavy menstrual bleeding. 
 
Figure 6 Investigative algorithms for patients with chronic AUB during the 
reproductive years. (A) Initial investigation comprises a structured history, physical 
examination, and the use of appropriate ancillary investigations, in part based upon 
the history and physical assessment. Evidence suggesting an ovulatory disorder 
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prompts assessment for endocrinopathy, whereas a positive screening result for 
coagulopathy (Figure 7) will indicate the need for appropriate hematological 
assessment. A complete blood count should be performed on all women with the 
symptom of heavy menstrual bleeding. (B) A pragmatic guide to uterine assessment. 
If the initial evaluation (Figure 6A) suggests a low risk for coagulopathy, structural or 
malignant/premalignant change, patients may be presumed to have AUB-E or -O 
and offered appropriate treatment options. However, if there is an enhanced risk for 
endometrial hyperplasia or malignancy (left), endometrial sampling is recommended. 
If an adequate specimen is not obtained, hysteroscopic examination and biopsy is 
recommended. If there is an enhanced risk for a structural abnormality, transvaginal 
ultrasonography is the next step (right). If evaluation of the endometrium is 
suboptimal or there is a suggestion of an abnormality affecting the endometrial 
cavity, either hysteroscopy or contrast hysterosonography is indicated. MRI may be 
occasionally indicated if hysteroscopy or contrast hysterosonography are not 
feasible, such as in the case of virginal women. Abbreviations: AUB, abnormal 
uterine bleeding; MRI, magnetic resonance imaging; TVUS, transvaginal 
ultrasonography. 
 
Figure 7 Four examples of the use of a matrix to guide FIGO-based evaluation of 
patients with chronic AUB. (A) Patient with the symptom of heavy menstrual bleeding 
(duration of menses 10 days and perceived and affecting the patient’s quality of life). 
Contrast sonohysterography demonstrates a posterior Type 2 leiomyoma 1.85 by 
1.49 cm in diameter. All other investigations have been completed and are negative. 
Diagnosis: AUB-LSM. (B) Here the cycle length varies from 14 to 60 days, the 
duration of menstrual bleeding from 2 to 11 days, and the volume ranging from light 
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to heavy. Transvaginal sonography shows a posterior Type 6 leiomyoma. Other 
investigations are normal save the thyroid-stimulating hormone, which is elevated. 
Diagnosis: AUB-Lo; -O with the primary cause of AUB the ovulatory disorder 
secondary to hypothyroidism. (C) In this example the patient’s menstrual parameters 
are normal with the exception of her complaint of intermittent intermenstrual 
bleeding. Contrast sonohysterography shows an endometrial polyp and a Type 5 
leiomyoma (not shown). The hysteroscopic view at the time of the polypectomy is 
shown. Diagnosis: AUB-P; -Lo with the primary cause of the AUB the endometrial 
polyp. (D) This patient has the complaint of lifelong heavy menstrual bleeding that is 
becoming heavier, with clots, and associated with worsening dysmenorrhea that 
lasts the entire period. She has a history of easy bruising and frequently bleeds 
when brushing her teeth. Her menses are cyclically predictable with a normal cycle 
length of 33 days. Transvaginal ultrasonography shows a globular uterus, an 
asymmetrically thickened posterior myometrium, and fan-shaped shadowing. All of 
the coagulation parameters measured were abnormal, and consistent with vWD 
Type 1. Diagnosis: AUB-A, -C. 
Abbreviations: AUB, abnormal uterine bleeding; FIGO, International Federation of 
Gynecology and Obstetrics; vWD, von Willebrand disease. Images are used 
courtesy of Malcolm G. Munro. 
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Table 1 Summary of changes to FIGO System 1 (normal and abnormal uterine bleeding). 
 
 
Parameter Change 
Frequency Amenorrhea is now part of the frequency category. 
Regularity Refined definition of regularity 
 Normal variation (shortest to longest) 8 days 
 Sight variance depending in part on age 
Duration Now only two categories for duration 
 Normal: ≤8 days 
 Prolonged: >8 days 
Volume Definition of the symptom of HMB 
 NICE definition 
 Bleeding volume sufficient to interfere with the woman’s quality of life. 
Intermenstrual bleeding Definition of the symptom of inter-menstrual bleeding 
 Spontaneous bleeding occurring between menstrual periods. 
 Can be either cyclical, or random. 
 
 
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; HMB, heavy menstrual 
bleeding; NICE, National Institute of Care Excellence. 
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Table 2 Summary of changes to FIGO AUB System 2 Causes or Contributors to AUB in the 
Reproductive Years (PALM-COEIN). 
 
 
System 2 
category 
Change 
AUB-A Refined sonographic diagnostic criteria 
AUB-L Inclusion of Type 3 as a submucous leiomyoma 
 Type definitions and distinctions 
 Distinction between Types 0 and 1; 6 and 7 
 Distinction between Types 2 and 3; 4 and 5 
AUB-C No longer includes AUB associated with pharmacologic agents that impair blood coagulation 
which are now included in AUB-I 
AUB-I Now includes AUB associated with all iatrogenic processes including the use of 
pharmacological agents used for anticoagulation and those thought to interfere with 
ovulation. 
AUB-O Diagnostic threshold changes based upon the revisions of System 1, described above. 
 No longer includes ovulatory disorders associated with drugs known or suspected to interfere 
with ovulation 
AUB-N The name of the category has been changed from “Not Yet Classified” to Not Otherwise 
Classified. 
 There is a brief discussion of a potential new cause of AUB the so-called uterine “niche” or 
isthmocele following lower segment cesarean section 
 
 
Abbreviations: AUB, abnormal uterine bleeding; FIGO, International Federation of Gynecology and 
Obstetrics. 
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Table 3 Screening instrument for coagulopathies in women with the symptom of heavy menstrual 
bleeding. 
a,b 
 
 
Initial screening for an underlying disorder of hemostasis in patients with excessive menstrual 
bleeding should be by a structured history. A positive screening result comprises any of the following: 
c
 
1. Heavy menstrual bleeding since menarche 
2. One of the following: 
a Postpartum hemorrhage 
b Surgical related bleeding 
c Bleeding associated with dental work 
3. Two or more of the following symptoms: 
a Bruising 1–2 times per month 
b Epistaxis 1–2 times per month 
c Frequent gum bleeding 
d Family history of bleeding symptoms 
 
 
a
 Reproduced with permission from [45]. 
b
 This structured history-based instrument is 90% sensitive for the presence of a coagulopathy in 
women with the symptom of heavy menstrual bleeding. 
c
 Patients with a positive screening result should be considered for further evaluation including 
consultation with a hematologist and/or testing of von Willebrand factor and Ristocetin cofactor. 
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